Loading
A phase 1/2 trial of Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Kahr Medical, active and no longer recruiting.
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04440735 by Kahr Medical, with 125 participants planned, started 2020-10-07 and due to reach its primary completion in 2025-09. Interventions recorded: DSP107, Atezolizumab. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Atezolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Atezolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/